Trends in survival of ALS from a population-based registry

Abstract Objective: To assess survival of ALS patients in general and in selected demographic and clinical subgroups comparing two periods (1998–2000 vs. 2008–2010). Methods: Newly diagnosed adults resident of Lombardy, Northern Italy from a population-based registry were included. Data were collected on age at diagnosis, sex, site of onset, diagnostic delay, and El-Escorial diagnostic category. Patients were followed until death or last observation. Survival was evaluated using Kaplan–Meier curves and Cox’s proportional hazards models. Results: In 2008–2010 (267 patients), median survival was 2.4 years and 1-year, 2-year, 3-year and 5-year survival rates were 79%, 56%, 41% and 24%. Longer survival was associated with male sex, younger age, spinal onset, and longer diagnostic delay. Multivariable analysis confirmed higher death in 65–69yr (HR 2.8; 95% CI 1.4-5.6), 70–74yr (HR 3.2; 95% CI 1.6-6.3) and 75 + yr (HR 6.9; 95% CI 3.5-13.8) categories, compared to ≤49yr, in females (HR 1.4; 95% CI 1.02-1.8), compared to males, and in patients diagnosed after 6–12 months (HR 1.9; 95% CI 1.4-2.7), compared with longer diagnostic delay. In 1998–2000 (235 patients), median survival was 2.2 years. The 1-year, 2-year, 3-year and 5-year survival rates were 77%, 53%, 38% and 20%. When adjusting for demographic and clinical variables, the HR for death in 2008–2010 versus 1998–2000 was 0.80 (95% CI 0.66–0.98). A significant increase of survival in 2008–2010 was found only in patients aged 50–59yr and 70–74yr at diagnosis. Conclusions: Survival of ALS has increased over time in the last decades, especially in middle aged and elderly patients. The benefits of comprehensive care in selected age groups might explain our findings.

[1]  S. Pal,et al.  Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.

[2]  F. Fang,et al.  Epidemiology of amyotrophic lateral sclerosis: an update of recent literature , 2019, Current opinion in neurology.

[3]  A. Chiò,et al.  Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients , 2019, Front. Neurosci..

[4]  T. H. Nguyen,et al.  Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[5]  Karel G M Moons,et al.  Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model , 2018, The Lancet Neurology.

[6]  E. Granieri,et al.  Riluzole and other prognostic factors in ALS: a population-based registry study in Italy , 2018, Journal of Neurology.

[7]  Adriano Chiò,et al.  Secular Trends of Amyotrophic Lateral Sclerosis: The Piemonte and Valle d’Aosta Register , 2017, JAMA neurology.

[8]  N. Pearce,et al.  The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[9]  E. Beghi,et al.  Is firstly diagnosed ALS really ALS? Results of a population-based study with long-term follow-up , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[10]  Sarah Martin,et al.  The changing picture of amyotrophic lateral sclerosis: lessons from European registers , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  Jarvis T. Chen,et al.  Race/ethnicity, socioeconomic status, and ALS mortality in the United States , 2016, Neurology.

[12]  A. Al-Chalabi,et al.  C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  M. Sormani,et al.  Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[14]  Marie-Claude Babron,et al.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin , 2016, European Journal of Epidemiology.

[15]  P. English,et al.  Survival and Cause of Death among a Cohort of Confirmed Amyotrophic Lateral Sclerosis Cases , 2015, PloS one.

[16]  Rui Huang,et al.  The predictors of survival in Chinese amyotrophic lateral sclerosis patients , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[17]  J. Wöhrle,et al.  Factors Predicting Survival in ALS Patients - Data from a Population-Based Registry in Rhineland-Palatinate, Germany , 2015, Neuroepidemiology.

[18]  O. Hardiman,et al.  A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  E. Beghi,et al.  Long‐term survival in amyotrophic lateral sclerosis: A population‐based study , 2014, Annals of neurology.

[20]  A. Chiò,et al.  Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995–2009 , 2013, Journal of Neurology.

[21]  M. Carone,et al.  Patients who survive 5 years or more with ALS in Olmsted County, 1925–2004 , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  D. Schoenfeld,et al.  The natural history of ALS is changing: Improved survival , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[23]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[24]  E. Beghi,et al.  Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[25]  E. Beghi,et al.  Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[26]  E. Beghi,et al.  Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  E. Beghi,et al.  Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy , 2007, European journal of neurology.

[28]  E. Beghi,et al.  Incidence of ALS in Lombardy, Italy , 2007, Neurology.

[29]  S. Appel,et al.  Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? , 2006, Archives of neurology.

[30]  V. Meininger,et al.  Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[31]  P. Kaufmann,et al.  The ALSFRSr predicts survival time in an ALS clinic population , 2005, Neurology.

[32]  R. Forbes,et al.  Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  G. Filippini,et al.  Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[34]  Adriano Chiò,et al.  Acute migraine treatment with droperidol , 2003, Neurology.

[35]  O. Hardiman,et al.  Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000 , 2003, Journal of neurology, neurosurgery, and psychiatry.

[36]  A. Al-Chalabi,et al.  Prolonged survival in motor neuron disease: a descriptive study of the King’s database 1990–2002 , 2003, Journal of neurology, neurosurgery, and psychiatry.

[37]  W. Robberecht,et al.  Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. , 2000, Acta neurologica Belgica.

[38]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[39]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[40]  J. Slattery,et al.  The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register , 1993, Journal of Neurology.

[41]  A. Chiò,et al.  Factors predicting survival in ALS: a multicenter Italian study , 2016, Journal of Neurology.